|
KMID : 0614020080230010001
|
|
Journal of Pharmaceutical Sciences (C.N.U.)
2008 Volume.23 No. 1 p.1 ~ p.14
|
|
|
Gene Therapy for Cardiovascular Disease
|
|
Myung Chang-Seon
|
|
|
Abstract
|
|
|
|
On the basis of developing knowledges in molecular and cellular cardiology, cardiac gene therapy has already been investigated and approved for cardiovascular diseases in animal studies. Studies for cardiac gene therapy have developed different gene-delivering vector systems. Non-viral vector systems such as plasmid DNA allow remarkable organ specificity, however, they are often limited by low transfection efficiency and transient gene expression. Viral vector systems allow high transfection efficiency, however, they are low organ-specific and limited to use owing to their immunogenicities. Recently, using advanced transcriptional and transductional targeting strategies, viral vectors have been improved and, moreover, more efficient serotypes of adeno-associated viruses(AAV) have been identified that show increased transduction rates, thus reducing the necessity for high virus titers. Many other modified vectors are being developed to overcome the obstacles of gene therapy. This review article will give a broad overview of the technical aspects of cardiovascular gene therapy including viral/non-viral vectors, a control of endothelium cell function, smooth muscle cell inhibition, therapeutic angiogenesis, modification of progenitor cells, and tissue engineered vascular conduits, and will discuss clinical trials and direction of future studies.
|
|
|
KEYWORD
|
|
|
cardiovascular disease, gene therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|